Bisphosphonate–polyaspartamide conjugates as bone targeted drug delivery systems. Issue 2 (11th November 2014)

• Record Type: Journal Article
• Authors: Paolino, D.; Licciardi, M.; Celia, C.; Giammona, G.; Fresta, M.; Cavallaro, G.
• Is Part Of: Journal of materials chemistry. Volume 3:Issue 2(2015)
• Page Start: 250
• Page End: 259
• Publication Date: 2014-11-11
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c4tb00955j
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Poly-hydroxy-aspartamide was used as a backbone to synthesize bisphosphonate derivatives thus achieving macromolecular carriers to be potentially used as targeting agents for bone drug delivery. Abstract : Poly-hydroxy-aspartamide was used as a backbone to synthesize bisphosphonate derivatives thus achieving macromolecular carriers to be potentially used as targeting agents for bone drug delivery. Molecules bearing bisphosphonate groups, such as aminobisphosphonate (ABP) and neridronate (NRD), have been conjugated to polyaspartamide (α, β-poly( N -2-hydroxyethyl)-dl -aspartamide, PHEA), with or without a spacer (succinic acid or 6-aminocaproic acid) thus obtaining PHEA-succinate-ABP and PHEA-caproylcarbamate-ABP and PHEA-ABP and PHEA-NRD, respectively. Bisphosphonate–polymer conjugates were physico-chemically characterized using size exclusion chromatography and 1 H-NMR; and their in vitro and ex vivo affinity for bone tissue has been further tested using the hydroxylapatite and rabbit bone binding assays, respectively. In vivo studies were carried out using rats to evaluate the biodistribution features of bisphosphonate–polymer conjugates in comparison with the starting PHEA. In vivo findings evidenced a suitable selectivity of bisphosphonate–polymer conjugates toward the bone tissues also as a function of time.